Literature DB >> 25176145

Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH).

Susan T Paulukonis1, William T Harris, Thomas D Coates, Lynne Neumayr, Marsha Treadwell, Elliott Vichinsky, Lisa B Feuchtbaum.   

Abstract

BACKGROUND: There are no population-based surveillance systems to determine prevalence, impact or outcomes in sickle cell disease (SCD). Estimates of the SCD population in California range broadly from 4,500 to 7,000, and little is known about their health status, health care utilization or health outcomes. A surveillance strategy was implemented using diverse data sources to develop a multi-dimensional, state-based surveillance system for SCD that includes adults and children and describes utilization, treatment and outcomes. PROCEDURE: Data from California newborn screening, inpatient and emergency room records, Medi-Cal/Medicaid claims and two SCD special care centers were collected for 2004-2008. A multi-step, iterative linkage process was used to link and de-duplicate these data sources, and case definitions were used to categorize cases.
RESULTS: After linking and de-duplicating, there were 1,975 confirmed cases of SCD, 3,159 probable cases as well as 8,024 possible cases. Among individual data sources, newborn screening and data from clinics contributed the greatest number of unique cases to the total. Select analyses of utilization and treatments for the population are described.
CONCLUSIONS: Using linked existing data sources, an estimate of the statewide count of the SCD population is possible. The approach can be used to create an in-depth health status profile of the affected population by aggregating utilization, treatment, and outcomes data including mortality and morbidity information. This effort sets the stage for development of an on-going, state-based surveillance system.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  California; data linkage; public health surveillance; sickle cell disease

Mesh:

Year:  2014        PMID: 25176145     DOI: 10.1002/pbc.25208

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  19 in total

1.  Identification of patients with hemoglobin SS/Sβ0 thalassemia disease and pain crises within electronic health records.

Authors:  Ashima Singh; Javier Mora; Julie A Panepinto
Journal:  Blood Adv       Date:  2018-06-12

2.  Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis.

Authors:  Jifang Zhou; Jin Han; Edith A Nutescu; William L Galanter; Surrey M Walton; Victor R Gordeuk; Santosh L Saraf; Gregory S Calip
Journal:  Br J Haematol       Date:  2019-02-03       Impact factor: 6.998

3.  Emergency department utilization by Californians with sickle cell disease, 2005-2014.

Authors:  Susan T Paulukonis; Lisa B Feuchtbaum; Thomas D Coates; Lynne D Neumayr; Marsha J Treadwell; Elliott P Vichinsky; Mary M Hulihan
Journal:  Pediatr Blood Cancer       Date:  2016-12-21       Impact factor: 3.167

4.  Increased risk of leukemia among sickle cell disease patients in California.

Authors:  Ann Brunson; Theresa H M Keegan; Heejung Bang; Anjlee Mahajan; Susan Paulukonis; Ted Wun
Journal:  Blood       Date:  2017-08-22       Impact factor: 22.113

5.  Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California.

Authors:  Oyebimpe Adesina; Ann Brunson; Theresa H M Keegan; Ted Wun
Journal:  Blood Adv       Date:  2017-07-11

6.  Bleeding in patients with sickle cell disease: a population-based study.

Authors:  Nisha Hariharan; Ann Brunson; Anjlee Mahajan; Theresa H M Keegan; Ted Wun
Journal:  Blood Adv       Date:  2020-03-10

7.  Characterization of opioid use in sickle cell disease.

Authors:  Jin Han; Jifang Zhou; Santosh L Saraf; Victor R Gordeuk; Gregory S Calip
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-08-16       Impact factor: 2.890

8.  Performance of ICD-10-CM diagnosis codes for identifying children with Sickle Cell Anemia.

Authors:  Sarah L Reeves; Brian Madden; Meng Wu; Lauren S Miller; David Anders; Michele Caggana; Lindsay W Cogan; Mary Kleyn; Isabel Hurden; Gary L Freed; Kevin J Dombkowski
Journal:  Health Serv Res       Date:  2020-01-09       Impact factor: 3.402

9.  Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.

Authors:  Susan T Paulukonis; James R Eckman; Angela B Snyder; Ward Hagar; Lisa B Feuchtbaum; Mei Zhou; Althea M Grant; Mary M Hulihan
Journal:  Public Health Rep       Date:  2016 Mar-Apr       Impact factor: 2.792

10.  Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.

Authors:  Jifang Zhou; Jin Han; Edith A Nutescu; Victor R Gordeuk; Santosh L Saraf; Gregory S Calip
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.